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Abstract
Background: Bacterial sexually transmitted infections may facilitate HIV transmission. 
Bacterial sexually transmitted infection testing is recommended for sexually active HIV-infected 
patients annually and more frequently for those at elevated sexual risk. We estimated percentages 
of HIV-infected patients in the United States receiving at least one syphilis, gonorrhea, or 
chlamydia test, and repeat (≥2 tests, ≥3 months apart) tests for any of these sexually transmitted 
infections from mid-2008 through mid-2010.
Design: The Medical Monitoring Project collects behavioral and clinical characteristics of HIV-
infected adults receiving medical care in the United States using nationally representative 
sampling.
Methods: Sexual activity included self-reported oral, vaginal, or anal sex in the past 12 months. 
Participants reporting more than 1 sexual partner or illicit drug use before/during sex in the past 
year were classified as having elevated sexual risk. Among participants with only 1 sex partner and 
no drug use before/during sex, those reporting consistent condom use were classified as low risk; 
those reporting sex without a condom (or for whom this was unknown) were classified as at 
elevated sexual risk only if they considered their sex partner to be a casual partner, or if their 
partner was HIV-negative or partner HIV status was unknown. Bacterial sexually transmitted 
infection testing was ascertained through medical record abstraction.
Results: Among sexually active patients, 55% were tested at least once in 12 months for syphilis, 
whereas 23% and 24% received at least one gonorrhea and chlamydia test, respectively. Syphilis 
testing did not vary by sex/sexual orientation. Receipt of at least 3 CD4+ T-lymphocyte cell counts 
Correspondence: Elaine W. Flagg, PhD, MS, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS E-63, Atlanta, GA 
30333. eflagg@cdc.gov.
Alternate author: Jacek Skarbinski, MD, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS E-46, Atlanta, GA 
30333.
Publisher's Disclaimer: Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily 
represent the official position of the Centers for Disease Control and Prevention.
Conflict of interest: None declared.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files 
are provided in the HTML text of this article on the journal’s Web site (http://www.stdjournal.com).
HHS Public Access
Author manuscript
Sex Transm Dis. Author manuscript; available in PMC 2019 December 19.
Published in final edited form as:
Sex Transm Dis. 2015 April ; 42(4): 171–179. doi:10.1097/OLQ.0000000000000260.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and/or HIV viral load tests in 12 months was associated with syphilis testing in men who have sex 
with men (MSM), men who have sex with women only, and women. Chlamydia testing was 
significantly higher in sexually active women (30%) compared with men who have sex with 
women only (19%), but not compared with MSM (22%). Forty-six percent of MSM were at 
elevated sexual risk; 26% of these MSM received repeat syphilis testing, whereas repeat testing for 
gonorrhea and chlamydia was only 7% for each infection.
Conclusions: Bacterial sexually transmitted infection testing among sexually active HIV-
infected patients was low, particularly for those at elevated sexual risk. Patient encounters in which 
CD4+ T-lymphocyte cell counts and/or HIV viral load testing occurs present opportunities for 
increased bacterial sexually transmitted infection testing.
Bacterial sexually transmitted infections (BSTIs) may facilitate HIV transmission1 by 
increasing plasma HIV viremia2,3 and HIV shedding in the genital tract.4,5 Incident BSTIs 
among HIV-infected persons also indicate recent risky sexual behavior that may result in 
HIV transmission.6,7 Thus, early detection and treatment of BSTI may contribute to 
reducing HIV transmission,7 and afford opportunities for risk reduction counseling.8
National guidelines recommend annual BSTI testing for sexually active HIV-infected 
patients and more frequent testing for those at elevated risk for BSTI.9–11 The Infectious 
Diseases Society of America (IDSA) primary care guidelines for management of HIV-
infected persons were first published in 200412 and were updated in 200913 and 2013.9 In 
the 2004 and 2009 guidelines, annual testing was recommended for all sexually active 
patients and repeat testing at 3- to 6-month intervals for patients with risk behaviors 
including multiple or anonymous sex partners and “other behaviors associated with 
transmission” of HIV and BSTI. The 2013 IDSA guidelines recommend annual BSTI testing 
for patients “at risk for infection” and repeat screening “depending on symptoms and signs, 
behavioral risk, and possible exposures.”9 A separate set of guidelines for prevention and 
treatment of opportunistic infections in HIV-infected adults and adolescents, published by 
the Centers for Disease Control and Prevention (CDC), the National Institutes of Health, and 
IDSA in April 2009,14 specifically recommended syphilis screening every 3 to 6 months for 
those reporting multiple sex partners, condomless sex, or sex in conjunction with illicit drug 
use, and for those using methamphetamines or with partners participating in these activities.
Studies conducted in a limited number of clinical settings indicate that BSTI screening in 
HIV-infected patients may be suboptimal, particularly for gonorrhea and chlamydia,15–19 
and these studies, which typically were conducted in large, primarily urban HIV clinics, may 
not sufficiently account for geographic variation or represent BSTI testing practices for 
patients receiving care in suburban or rural communities. There are no national estimates of 
BSTI testing among HIV-infected persons; thus, we estimated percentages of HIV-infected 
patients in the United States (US) receiving at least one test for syphilis, gonorrhea, or 
chlamydia, and repeat tests for these infections, during a 12-month period, and examined 
differences in testing by demographic, sexual, and other factors.
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METHODS
The Medical Monitoring Project (MMP) is a complex-sample, cross-sectional survey 
designed to produce nationally representative estimates of behavioral and clinical 
characteristics of HIV-infected adults receiving medical care in the United States.20 States 
and territories were sampled first, followed by facilities providing HIV care, and then by 
HIV-infected adults (aged ≥18 years) who had at least 1 medical care visit from January to 
April 2009 at participating facilities. Data were collected using face-to-face interviews about 
self-reported patient experiences and behaviors for the past 12 months; interviews were 
conducted between June 2009 and May 2010. Medical record abstraction was used to collect 
data on clinical care received in the 12 months preceding interview.
All sampled states and territories participated in MMP.20 Of 603 sampled facilities, 461 
participated (facility-level response rate, 76%). Of 9338 sampled patients, 4217 completed 
interviews and had their medical records abstracted (patient-level response rate, 51%). Data 
were weighted based on known probabilities of selection at state/territory, facility, and 
patient levels, and to adjust for nonresponse.21,22 Participants in the 2009 data collection 
cycle were estimated to represent a population of 421,186 (95% confidence interval [CI], 
378,187–464,186) HIV-infected adults receiving medical care in the United States from 
January to April 2009.
We defined syphilis testing in 2 ways: (1) medical record documentation of at least one 
syphilis (treponemal or nontreponemal) test within the 12 months before interview and (2) 
documentation of repeat syphilis tests (≥2 tests, >3 months apart) in the same period. The 
same criteria were used to define gonorrhea and chlamydia testing, regardless of anatomical 
site of specimen collection. We also created a variable for medical record documentation of 
at least 3 CD4+ T-lymphocyte cell count and/or HIV viral load (CD4/VL) tests, all 3 months 
apart or longer, within the 12 months before interview.
Sex, sexual behavior, and sexual orientation were self-reported. We created 4 mutually 
exclusive sex/sexual orientation categories: gay, bisexual, and other men who have sex with 
men (MSM), men who have sex with women only (MSW), women, and transgender or other 
participants. Results reported for all participants include those for transgender/other 
participants; however, because of the small number of these participants (n = 62), this group 
was excluded from sex/sexual orientation–specific estimates. Demographic variables for age 
group and race/ethnicity were self-reported.
Interview questions on sexual activity and sexual risk behaviors in the past 12 months were 
used to create 2 indicator variables: any sexual activity (oral, vaginal, and/or anal; Fig. 1A) 
and sexual activity associated with elevated risk of BSTI or HIV transmission. For the latter 
variable, participants reporting more than 1 sexual partner or illicit drug use before/during 
sex in the past 12 months were classified as having elevated sexual risk (Fig. 1A, B). Among 
participants with only 1 sex partner and no drug use before/during sex, those reporting 
consistent condom use were classified as low risk; those reporting sex without a condom (or 
for whom this was unknown) were classified as at elevated risk if they considered their sex 
partner to be a casual partner, or if their partner was HIV negative or of unknown HIV status 
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(Fig. 1B). Twenty-one participants did not respond to questions assessing sexual activity, 
and 29 sexually active participants did not provide sufficient information to classify their 
sexual activity as low or elevated risk.
Analyses were conducted using SAS 9.3 (SAS Institute Inc, Cary, NC; http://www.sas.com/
en_us/home.html) and SAS-callable SUDAAN 11.0 (Research Triangle Institute, Research 
Triangle Park, NC; http://www.rti.org/sudaan/) to account for increased variance from the 
complex-sample design.
We conducted descriptive analyses and estimated weighted percentages of those receiving at 
least one and repeat syphilis, gonorrhea, and chlamydia tests by sex/sexual orientation for all 
patients, for those reporting any sexual activity, and for those at elevated sexual risk. Among 
those reporting any sexual activity and those at elevated risk, we conducted bivariate 
analyses of percentages tested by demographic and other factors. Multivariable logistic 
regression was used to generate prevalence ratios. Tests of significance (including CI) were 
adjusted for multiple comparisons using the Bonferroni method; different P values, for 
different BSTI, were used as thresholds for statistical significance (see Supplementary 
Material, http://links.lww.com/OLQ/A103).23
The MMP was determined by CDC to be a nonresearch, public health surveillance activity24 
and was reviewed and approved by CDC accordingly. Participating states/territories and 
facilities obtained local institutional review board approval to conduct MMP if required 
locally, and informed consent was obtained from all interviewed participants.
RESULTS
Demographic, Sexual, and Other Attributes by Sex/Sexual Orientation
Patients were 47% MSM, 23% MSW, 27% women, and 3% transgender/other. Most patients 
(86%) were 35 years of age or older (Table 1). Age and race/ethnicity distributions varied 
significantly between MSM, MSW, and women. Most patients (62%) had at least 3 CD4/VL 
tests in the past 12 months.
Most patients (62%) engaged in sexual activity in the past 12 months; this was significantly 
higher for MSM (70%) compared with MSW (56%, P < 0.001) and women (55%, P < 
0.001). Overall, 34% of patients were classified as at elevated sexual risk: 46% of MSM, 
compared with 23% of MSW (P < 0.001) and 22% of women (P < 0.001). Of those 
engaging in sex, 66% of MSM were at elevated risk, compared with 42% of MSW (P < 
0.001) and 40% of women (P < 0.001).
At Least One BSTI Test and Repeat BSTI Testing, by Sexual Risk and Sex/Sexual 
Orientation
Fifty-two percent of all patients received at least one syphilis test in 12 months; this 
increased only slightly for those reporting any sex (55%) and those at elevated sexual risk 
(58%), and did not vary significantly by sex/sexual orientation (Table 2). Among those 
reporting no sex, 45% of MSM, 50% of MSW, and 45% of women were tested for syphilis. 
Rates of receiving at least one gonorrhea or chlamydia test were lower than for syphilis; only 
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26% of patients at elevated sexual risk received either test. Rates of receiving at least one 
chlamydia test were significantly higher among women reporting any sex (30%) compared 
with sexually active MSW (19%, P < 0.001), but these rates did not differ from those for 
sexually active MSM (22%).
Rates of repeat syphilis testing were much lower than rates of receipt of at least one test; 
only 19% of those reporting any sex and 23% of those at elevated sexual risk received repeat 
testing. Among all patients, repeat syphilis testing was significantly higher in MSM (20%) 
compared with MSW (14%, P < 0.001) and women (12%, P < 0.001). Among those 
reporting any sex and those at elevated sexual risk, repeat syphilis testing was significantly 
higher for MSM (23% and 26%, respectively) compared with women (12% [P < 0.001] and 
13% [P < 0.001]), but not compared with MSW (16% and 19%). Repeat testing for 
gonorrhea (7%) and chlamydia (6%) was extremely low among all patients at elevated risk 
and did not vary by sex/sexual orientation.
Receipt of at Least One BSTI Test Among Patients Reporting any Sexual Activity, by Sex/
Sexual Orientation and Demographic and Other Attributes
Although the percentage of patients receiving at least one test for each BSTI was somewhat 
higher among sexually active patients aged 18 to 34 years, rates were not significantly 
different from those 35 years or older (Table 3). There were no significant differences in 
BSTI testing across sexes/sexual orientations within either age group. Among women, 
receipt of at least one chlamydia test was significantly higher for very young women aged 18 
to 24 years (63%) compared with those 25 years or older (29%, P < 0.001); although testing 
was dissimilar by these age groups for gonorrhea (52% and 27%, respectively) and syphilis 
(61% and 49%), these differences were not statistically significant.
Among sexually active MSM, receipt of at least one test for each BSTI was significantly 
higher for Hispanics compared with non-Hispanic whites; gonorrhea and chlamydia testing 
also was higher for those of other race/ethnicity compared with whites. BSTI testing did not 
vary by race/ethnicity for MSW. Among women, syphilis and gonorrhea testing was higher 
for sexually active non-Hispanic blacks (55% and 32%, respectively) compared with whites 
(30% and 16%, respectively; P < 0.001 for each comparison). Among non-Hispanic whites, 
receipt of at least one syphilis test was significantly higher for MSM compared with women 
(P < 0.001), but BSTI testing did not differ by sex/sexual orientation within other race/
ethnicities.
Receipt of at least 3 CD4/VL tests in the past 12 months was associated with significantly 
higher rates of at least one syphilis test among sexually active MSM (65%), MSW (62%), 
and women (57%), compared with 0 to 2 CD4/VL tests (46%, 39%, and 36%, respectively; 
P < 0.001 for each comparison). Rates of having at least one test for gonorrhea and 
chlamydia, while lower than for syphilis, were also higher for those with at least 3 annual 
CD4/VL tests among MSM and women, but not MSW. Among those with at least 3 
CD4/VL tests, comparisons across sex/sexual orientation for each BSTI showed that only 
chlamydia testing was significantly higher in women (37%) compared with MSW (22%, P < 
0.001).
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Repeat BSTI Testing Among Patients at Elevated Sexual Risk, by Sex/Sexual Orientation 
and Demographic and Other Attributes
Among those at elevated sexual risk, repeat testing for each BSTI varied significantly by age 
group only among women; those aged 18 to 34 years had higher testing rates than older 
women (Table 4). Comparisons across sex/sexual orientation showed that repeat syphilis 
testing was higher in older MSM (25%) compared with older women (8%, P < 0.001). 
Gonorrhea and chlamydia testing did not vary by sex/sexual orientation within either age 
group.
Repeat testing did not differ by race/ethnicity for MSM, MSW, or women for any BSTI 
(Table 4). Comparisons across sex/sexual orientation indicated that among Hispanics at 
elevated risk, repeat syphilis testing was higher in MSM (37%) compared with women (6%, 
P < 0.001).
Repeat testing for each BSTI was significantly higher among MSM at elevated sexual risk 
who received at least 3 annual CD4/VL tests, compared with those with 0 to 2 tests. Among 
MSW and women, having at least 3 CD4/VL tests was only significantly associated with 
increased repeat syphilis testing. Comparisons across sexes/sexual orientations showed that 
among those with 0 to 2 CD4/VL tests, MSM had higher rates of repeat syphilis testing 
(12%) than MSW (3%, P = 0.001) and women (1%, P < 0.001).
DISCUSSION
Most HIV-infected patients in the United States engaged in sexual activity during the past 12 
months; almost half of MSM and almost one quarter of MSW and women were at elevated 
sexual risk. Among those engaging in sex, 66% of MSM and approximately 40% of MSW 
and women were at elevated risk. However, testing for BSTI among HIV-infected patients 
was low and did not substantially increase for those at elevated risk. Only 55% of sexually 
active patients received at least one test for syphilis, and approximately one quarter received 
at least one gonorrhea or chlamydia test. Repeat BSTI testing was low for each BSTI 
examined, particularly gonorrhea and chlamydia.
The 200412 and 200913 IDSA primary care guidelines for management of HIV-infected 
persons were available when participants in this study received medical care (mid-2008 
through mid-2010). In both of these guidelines, annual testing was recommended for all 
sexually active patients and repeat testing at 3- to 6-month intervals for patients with risk 
behaviors including multiple or anonymous sex partners and “other behaviors associated 
with transmission” of HIV and BSTI. However, in other sections of these guidelines and in 
the guidelines published in 2013,9 BSTI screening recommendations after the initial patient 
encounter were based on behavioral risk and other factors, including infection with other 
BSTI and community prevalence of BSTI; these sections only specified that “more frequent 
testing may be indicated” for those at elevated risk for BSTI. It is possible that more 
consistent recommendations within and across guidelines would have resulted in higher 
testing rates than we observed.
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Higher rates of syphilis testing, compared with gonorrhea and chlamydia testing, may be 
partially due to provider awareness of increasing primary and secondary syphilis rates 
among US MSM since 2001. A high percentage of syphilis-infected MSM are coinfected 
with HIV,25 which may have influenced testing for all HIV-infected patients. Also, 
guidelines for the prevention and treatment of opportunistic infections in HIV-infected 
persons14 emphasized syphilis testing, which may have contributed to provider awareness. 
However, these were first published in April 2009 and thus were only available for part of 
our data collection period.
Provider awareness of increasing syphilis infections among MSM also may partially account 
for the higher rates of repeat syphilis testing in MSM, compared with MSW and women. 
Early syphilis infection continued to increase among MSM in 2007 to 2012; among MSW 
and women, infection rates increased in 2007 to 2008, but declined from 2008 to 2012.26 
Surveillance data from 2005 to 2008 in 27 states indicate that increases in syphilis infections 
have been highest among MSM aged 15 to 29 years27; however, this information, which was 
published in 2011, would not have been widely disseminated during our study period. We 
did not find significant variation in receipt of at least one syphilis test, or repeat syphilis 
testing, among sexually active HIV-infected MSM aged 18 to 34 years compared with those 
35 years or older.
Receipt of at least one chlamydia test among sexually active women was significantly higher 
than among comparable MSW. The US Preventive Services Taskforce recommends annual 
chlamydia screening for all sexually active women younger than 25 years28; gonorrhea 
screening is recommended only for women at increased risk for infection.29 We found that 
more sexually active women aged 18 to 24 years received at least one chlamydia test (63%) 
compared with those aged 25 years or older (29%). The chlamydia testing rate we observed 
in young women was much higher than the 2006 to 2008 national estimate of 38% for 
sexually active women aged 15 to 25 years, derived from self-report.30 Provider awareness 
of the need for chlamydia screening in sexually active younger women may have partially 
accounted for this finding.
BSTI screening guidelines and counseling cannot be appropriately implemented without 
periodically conducting a sexual risk assessment.7 Less than half of MMP participants 
reported receiving individual-level HIV or BSTI prevention counseling from health care 
providers.31 It is possible that the proportion of patients receiving sexual risk assessment 
was similarly low because approximately half of patients reporting no sexual activity 
received a syphilis test. Barriers to conducting sexual histories may include time constraints, 
language and cultural barriers, patient confidentiality concerns, and provider and/or patient 
hesitancy to discuss sexuality.32 The MMP patient interview collected detailed information 
on patient sexual history using protocols to ensure strict confidentiality. It is possible that 
some patients we identified as having any sex or elevated sexual risk were not similarly 
identified by their clinicians, and therefore, appropriate BSTI testing was not performed. 
Some patients may have been offered BSTI testing but declined.
Other barriers to conducting BSTI testing may include provider disagreement with national 
guidelines or low prioritization of screening by providers. Interventions to increase BSTI 
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screening such as provider adoption of standard testing protocols, or alerts and prompts 
incorporated into electronic medical records, may be effective additions to national 
guidelines. Clinical decision support systems that use software algorithms to generate 
patient-specific recommendations have been shown to improve HIV provider practice33 and 
increase BSTI testing in MSM.34
Repeat CD4/VL testing was associated with increased receipt of at least one syphilis test and 
with repeat syphilis testing in MSM, MSW, and women. Syphilis tests are serologic and thus 
can be easily ordered during the same encounter in which CD4/VL tests are ordered; 
gonorrhea and chlamydia testing requires additional specimen collection, which may 
partially account for lower levels of testing. However, we did observe increases in receipt of 
at least one gonorrhea or chlamydia test with increased CD4/VL testing in MSM and 
women, and with repeat testing for these BSTIs in MSM. This may be a function of more 
frequent patient encounters, and therefore more opportunities to order these tests. More 
simply, CD4/VL and BSTI tests may both indicate high-quality HIV care.
This analysis was subject to several limitations. The population of inference is HIV-infected 
adults receiving medical care and therefore does not reflect rates of BSTI testing among all 
HIV-infected adults, including those not engaged in medical care, which are likely to be 
lower. Moreover, our patient response rate was moderate; however, samples with moderate 
response rates that are selected from well-constructed frames have reduced overall risk of 
bias.21 We assessed and adjusted for nonresponse using widely accepted techniques,22 but 
the possibility of residual bias in either direction remains. These data, reflecting patient care 
from mid-2008 through mid-2010, also may not represent current BSTI testing rates.
It is possible that some patients sought BSTI testing at a sexually transmitted disease clinic 
or community-based health care organization, rather than from their HIV care provider, 
perhaps due to concerns regarding confidentiality or cost of testing and/or treatment; tests 
conducted at these facilities would not have been included in our data. We also were unable 
to distinguish follow-up BSTI tests (e.g., tests of cure) from screening/diagnostic tests. It is 
possible that tests occurring early in an individual’s 12-month surveillance period were 
follow-up tests for previously diagnosed BSTI, and therefore our findings may somewhat 
overestimate true screening or diagnostic testing. This may be of less concern for repeat 
BSTI tests, which we defined as being at least 3 months apart.
We also could not examine gonorrhea and chlamydia testing for rectal and pharyngeal 
specimens because information on anatomical site of specimen collection was missing for 
38% and 37% of participants who received at least one gonorrhea or chlamydia test, 
respectively. This information may be missing for so many participants because these data 
often would have been abstracted from laboratory request and/or report forms; it is possible 
that some of these forms may not have included fields for anatomical site because nucleic 
acid amplification tests are not Food and Drug Administration cleared for use on rectal and 
pharyngeal specimens (although some laboratories have established performance 
specifications for using nucleic acid amplification tests with these specimens).35 Even if a 
field (or fields) for specification of anatomical site was included on the laboratory request 
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form, this information may not have been provided by some clinicians for extragenital 
specimens for this reason.
We could not use multivariable modeling to determine which demographic and other factors 
were most strongly associated with BSTI testing, due to differences in rates of testing by age 
group, race/ethnicity, and sex/sexual orientation (i.e., effect modification); after the data 
were stratified by these factors, insufficient numbers of records were available in several 
strata to provide sufficient power for such statistical analysis. However, we minimized 
spurious associations by using more conservative significance levels for our statistical 
comparisons (and consequently increasing the width of confidence limits for these 
comparisons) to account for the number of comparisons we conducted.
This study also had several strengths. We were able to estimate population rates of BSTI 
testing among HIV-infected adults in care in the US and to account for differences by sex/
sexual orientation and other factors. Other studies of BSTI testing among HIV-infected 
patients have been conducted in a small number of clinics15–19 or limited geographic areas,
16–19
 and, thus may not represent BSTI testing in the population of HIV-infected patients. 
Our rates of receipt of at least one syphilis test were lower than syphilis screening rates of 
66% to 76% for HIV-infected MSM from a 2004 to 2006 retrospective review of medical 
records in 8 large, urban HIV clinics in 6 cities,15 although testing rates for gonorrhea and 
chlamydia in these clinics were similar to ours. It is likely that provider awareness of the 
importance of syphilis screening was higher in these clinics, as most of them received Ryan 
White funding, for which syphilis screening is required as a quality-of-care measure.
In conclusion, rates of BSTI testing among sexually active HIV-infected patients were low, 
and repeat testing rates among those at elevated sexual risk were particularly low. Patient 
encounters in which CD4/VL testing is conducted present opportunities for BSTI testing. 
Additional interventions, such as alerts and prompts incorporated into electronic medical 
records, may be effective additions to national guidelines for improving BSTI testing.
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Figure 1. 
A, Sexual activity and risk classification—MMP, United States. B, Sexual risk classification 
among those reporting 1 sex partner in the past 12 months—MMP, United States.
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